Nasdaq exas.
Nov 22, 2023 · According to the issued ratings of 16 analysts in the last year, the consensus rating for Exact Sciences stock is Moderate Buy based on the current 4 hold ratings and 12 buy ratings for EXAS. The average twelve-month price prediction for Exact Sciences is $96.56 with a high price target of $130.00 and a low price target of $73.00.
Notable Tuesday Option Activity: LTH, DECK, EXAS. January 10, 2023 — 03:23 pm EST. Written by BNK Invest for BNK Invest ->. Looking at options trading activity among components of the Russell ...Nov 23, 2023 · EXACT Sciences Corporation (NASDAQ:EXAS) is a leading provider of cancer screening and diagnostic tests with a focus on early detection and prevention of colorectal cancer. It launched Cologuard ... Exact Sciences Corp. NASDAQ: EXAS is on a self-proclaimed mission to change the way cancer is detected and treated. The Madison, Wisconsin company is among the market's best price performers, advancin...EXAS EXAS AFTER HOURS QUOTE EXAS LATEST AFTER HOURS TRADES. ... Add symbols now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing stocks, funds and ETFs, ...
Find the latest Earnings Report Date for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com.WebDec 4, 2023 · December 4, 2023. Frontier Capital Management Co. LLC decreased its position in shares of Exact Sciences Co. ( NASDAQ:EXAS - Free Report) by 29.1% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 530,134 shares of the medical research company's stock after selling 217,832 shares during the period.
These dynamics opened the door for Exact Sciences (NASDAQ:EXAS) to serve a rapidly expanding subsector of the healthcare industry by developing and commercializing novel molecular diagnostic tests ...
Apr 24, 2023 · Fintel reports that on May 10, 2023, Craig-Hallum upgraded their outlook for Exact Sciences (NASDAQ:EXAS) from Hold to Buy.. Analyst Price Forecast Suggests 9.61% Upside. As of April 24, 2023, the ... Nov 30, 2023Fintel reports that on May 10, 2023, Craig-Hallum upgraded their outlook for Exact Sciences (NASDAQ:EXAS) from Hold to Buy.. Analyst Price Forecast Suggests 9.61% Upside. As of April 24, 2023, the ...TSLA. Tesla, Inc. Common Stock. $207.30 +1.54 +0.75%. Find the latest dividend history for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com. Exact Sciences Corp. (NASDAQ: EXAS) is on a self-proclaimed mission to change the way cancer is detected and treated. The Madison, Wisconsin company is among the market’s best price performers ...
Find the latest SEC Filings data for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com.
"Exact Sciences Corporation (NASDAQ:EXAS) is a cancer diagnostics company whose flagship product is Cologuard, a stool-based screening test for colon cancer. The stock declined because financial ...
20 Okt 2023 ... PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it will ...Exact Sciences Co. ( NASDAQ:EXAS – Get Free Report) was up 7.6% during trading on Friday . The company traded as high as $66.06 and last traded at $65.84. Approximately 1,116,388 shares changed hands during trading, a decline of 40% from the average daily volume of 1,860,572 shares. The stock had previously closed at $61.17.EXACT SCIENCES CORP ( EXAS) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 77% based on the firm’s underlying fundamentals and the stock’s ...Nov 25, 2023 · Exact Sciences (NASDAQ:EXAS) produces and sells diagnostic and cancer screening tests. The company is best known for its Cologuard product. That said, Exact Sciences has several other revenue ... Dec 1, 2023 · Get the latest Exact Sciences Corporation EXAS detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. ... NASDAQ data is at least 15 minutes delayed.
1 Mar 2017 ... Exact sciences rings the Nasdaq Closing Bell! $EXAS #CRCcountdown.127.60%. Get the latest Exact Sciences Corp (EXAS) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment...EXACT SCIENCES CORP ( EXAS) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 77% based on the firm’s underlying fundamentals and the stock’s ...EXACT SCIENCES CORP ( EXAS) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 77% based on the firm’s underlying fundamentals and the stock’s ...Exact Sciences EXAS is the $19 billion leader in proactive cancer diagnostics with the Cologuard screening kit, ... anywhere on Nasdaq.com. Start browsing stocks, funds and ETFs, ...Exact Sciences (NASDAQ:EXAS) produces and sells diagnostic and cancer screening tests. The company is best known for its Cologuard product. That said, Exact Sciences has several other revenue ...Exact Sciences (NASDAQ: EXAS) stock had tumbled nearly 27% over the last six months. Yet the company reported strong third-quarter financial results on Nov. 1 and has multiple strong positive ...
EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission. Find the latest Financials data for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com.As of March 2015, Theranos is a private company and does not have a public stock symbol. The medical technology company has a partnership with the public company, Walgreens, which has a stock symbol of WAG on Nasdaq.
The average one-year price target for EXAS / Exact Sciences Corp. is $112.948. The forecasts range from a low of $85.85 to a high of $136.5. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to ...Exact Sciences Corporation EXAS recently presented modeling data that shows Cologuard (mt-sDNA) as the most cost-effective colorectal cancer (CRC) detection and screening option at the 2021 ...Jan 12, 2023 · Exact Sciences' valuation has been plummeting. In 2022, shares of Exact Sciences fell 36%, underperforming the S&P 500, which declined by 19%. Exact Sciences isn't near its 52-week low of $29.27 ... Dec. 1, 2023, 07:35 AM. Leerink Partners analyst Puneet Souda maintained a Buy rating on Exact Sciences ( EXAS – Research Report) yesterday and set a price target of $115.00. …WebFeb 27, 2018 · ADVISORY, Feb. 27, 2018 (GLOBE NEWSWIRE) -- What: Exact Sciences Corp. (Nasdaq:EXAS), a molecular diagnostics company focused on the early detection and prevention of the deadliest forms of cancer, will open the Nasdaq Stock Market remotely from the Cologuard Classic, a PGA TOUR Champions event in Tucson, Arizona. EXAS NASDAQ. EXAS NASDAQ. EXAS NASDAQ. EXAS NASDAQ. Market closed Market closed. 67.03 USD R +3.03 +4.73%. At close at Dec 1, 16:58 UTC-8. USD. No trades. See on Supercharts. Overview . News . Ideas Financials Technicals Forecast . EXAS news flow. News didn't load. Looks like that didn't go very well. Let's try again.Exact Sciences (EXAS) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.90. This compares to loss of $1.28 per share a year ago. These figures ...Share $67.49 Nov 29, 10:10:29 AM GMT-5 · USD · NASDAQ · Disclaimer search Compare to Apple Inc $191.11 AAPL0.37% Pacific Biosciences of California Inc $8.85 PACB2.55% Amazon.com Inc $147.18...
NASDAQ: EXAS Exact Sciences. Market Cap. $12B. Today's Change (4.73%) $3.03. ... Still, here are two companies that could pull it off: Exact Sciences (EXAS 4.73%) and Airbnb (ABNB 6.87%). Let's ...
Dec 1, 2023 · Get the latest Exact Sciences Corporation EXAS detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. ... NASDAQ data is at least 15 minutes delayed.
This year, Exact Sciences (EXAS-1.63%) expects its revenue will total just under $2.1 billion. That means that in just five years, its top line will have grown by an incredible 683%. The company ...Importantly, Exact Sciences Corporation (NASDAQ:EXAS) does carry debt. But the more important question is: how much risk is that debt creating? Why Does Debt Bring Risk? Debt is a tool to help businesses grow, but if a business is incapable of paying off its lenders, then it exists at their mercy. If things get really bad, the lenders can take ...Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2023 financial results after ...Exact Sciences Corporation‘s (EXAS Quick Quote EXAS - Free Report) shares have surged 35.4% year to date against the industry’s decline of 21.2%. The …WebExact Sciences Corporation Common Stock (EXAS) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Find the latest Institutional Holdings data for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com.Exact Sciences Corporation (EXAS) NasdaqCM - NasdaqCM Real Time Price. Currency in USD. Follow. 2W 10W 9M. 67.03 +3.03 (+4.73%) At close: 04:00PM EST. 67.10 +0.07 (+0.10%) After hours: 07:58PM...Exact Sciences EXAS is the $19 billion leader in proactive cancer diagnostics with the Cologuard screening kit, ... anywhere on Nasdaq.com. Start browsing stocks, funds and ETFs, ...May 15, 2023 · Diagnostic and cancer test products provider Exact Sciences Corp. (NASDAQ: EXAS) saw its shares spike over 17% on its Q1 2023 earnings results. The company is known for its flagship colon cancer ...
At Stock Options Channel, our YieldBoost formula has looked up and down the EXAS options chain for the new August 26th contracts and identified one put and one call contract of particular interest ...May 11, 2023 · Shares of Exact Sciences ( EXAS 4.73%) stormed higher by 16.5% over the first three and a half days of trading this week, according to data provided by S&P Global Market Intelligence. The big gain ... Exact Sciences Company Info. EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non ... Instagram:https://instagram. nasdaq ataidental insurance in njchannel stocktight spread forex broker The latest price target for . Exact Sciences (NASDAQ: EXAS) was reported by Goldman Sachs on November 3, 2023.The analyst firm set a price target for $90.00 expecting EXAS to rise to within 12 ... sirius xm holdings inc. stockwww.marketwatch thai set NASDAQ EXAS opened at $67.03 on Friday. The company has a fifty day moving average of $64.55 and a two-hundred day moving average of $79.14. Exact Sciences Co. has a 1 year low of $43.68 and a 1 ... tecb etf EXAS Stock 12 Months Forecast. $95.46. (50.43% Upside) Based on 14 Wall Street analysts offering 12 month price targets for Exact Sciences in the last 3 months. The average price target is $95.46 with a high forecast of $120.00 and a low forecast of $80.00. The average price target represents a 50.43% change from the last price of $63.46.MADISON, Wis., Feb. 7, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS ), a leading provider of cancer screening and diagnostic tests, today announced the launch of the OncoExTra ...Exact Sciences EXAS is the $19 billion leader in proactive cancer diagnostics with the Cologuard screening kit, ... anywhere on Nasdaq.com. Start browsing stocks, funds and ETFs, ...